ASX Announcement **5 November 2026**

2026 Annual General Meeting – MD & CEO's Address

In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited (**Atomo)** attaches the MD & CEO's Address to be delivered at Atomo's 2026 Annual General Meeting.

For more information, please contact

Cheri Walker, PhD
Atomo Diagnostics
cheri.walker@atomodiagnostics.com
Phone: +61 2 9099 4750

For Media questions, please contact:

George Hazim
Director
Media and Public Affairs Australia
georgehazim@mediaaffairs.com.au
Phone: +61417516262

This announcement was authorised by the Managing Director & CEO on behalf of the Board

ATOMO DIAGNOSTICS

FY26 AGM PRESENTATION
5 NOVEMBER 2026



DISCLAIMER

This presentation has been prepared by Atomo Diagnostics Limited ("Atomo") based on information available as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment of Atomo as part of its own investigations.

This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral communications transmitted or otherwise made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information.

The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only.

This presentation may contain certain forward-looking statements that are based on Atomo's beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance, and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward-looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).


PURPOSE-LED INNOVATION BUILT ON CORE VALUES

OUR PURPOSE: ***Empowering healthier lives through fast, accurate, point of care testing***

OUR MISSION


Put the user experience at the centre of diagnostics—expanding equitable and affordable access to accurate diagnosis and a seamless pathway to treatment.

HOW WE WORK




IMPACT

Commercialise products that matter in point-of-care settings.




INNOVATION

Turn creative thinking into practical solutions.



INTEGRITY

Act with honesty and fairness in everything we do.



COLLABORATION

Work as one global team.



EXCELLENCE

Be recognised as experts in the field.

Five values translate Atomo's purpose into how the company innovates, partners and delivers.

WHO IS ATOMO AND WHAT DO WE DO?

Commercial-stage diagnostics company with a growing pipeline of proprietary and OEM partnerships

WHO IS ATOMO?

COMMERCIAL STAGE

DIAGNOSTIC COMPANY with approved professional and self-test point-of-care products sold across global markets.

DIFFERENTIATED TECHNOLOGY

Patented all-in-one blood collection solutions designed for superior usability, reliability and performance in decentralised testing.

PROVEN COMMERCIAL TRACTION

HIV GEN 3 | +21% FY26 YoY

5m+ tests supplied across 30+ countries.



WHAT BUSINESSES DO WE HAVE?

ATOMO PROPRIETARY PRODUCTS

Blood-based rapid tests sold globally through professional and self-test channels.

IN MARKET	**HIV Gen 3 franchise**
GROWING PIPELINE	Gen 4 HIV · Active Syphilis · Liver / ALT

POINT-OF-CARE TECHNOLOGIES | OEM


Integrated all-in-one and modular devices that help partners improve the usability and performance of blood-based tests.

FEBRIDX® DRIVES GROWTH	OEM revenue +209% FY26 YoY | 215 live US sites in Q1FY27
PARTNER PIPELINE	Pregnancy commercial · Ferritin and pre-hospital stroke in validation

SOLUTIONS THAT DELIVER

Next generation POCT devices that provide superior usability and performance

Initial solutions focused on transforming usability in the lateral flow market





Issues with Standard Multi-Component Test Kits

- Complex
  - Multiple components
  - Multiple user steps
  - Convoluted workflow
  - High error rates: 10%+ by professionals, 30%+ by untrained self-test users

Advantages of Atomo Devices

- Accurate & Reliable
  - Easy to use
  - Correct volume of blood and reagent
  - Seamless delivery to test strip
- Intuitive
  - Reduced error rate for untrained first-time users

ATOMO PLATFORM DRIVING ADOPTION OF RAPID TESTING


Focus on ease of use, speed of results and affordability

EASY TO USE
Simple to use products providing reliability and usability in decentralised settings

SPEED OF RESULTS
Rapid results with a high degree of accuracy

EASY TO OBTAIN & AFFORDABLE
Accessibility online and increasingly through retail and via healthcare professionals

Future of Point of Care & Rapid Testing [8]



Report - Comparative usability analysis of two rapid diagnostic self-test kits [9]

SOLUTIONS THAT DELIVER

Atomo offers three blood-based platforms driven by the market requirements

Each platform simplifies capillary blood collection and delivery; the key difference is how it integrates with the test cassette.

PASCAL

Integrated all-in-one platform



MOST INTEGRATED CONFIGURATION

- Built-in, auto-retracting safety lancet
- Precise button-activated buffer delivery
- Interlocked steps help reduce user error
- 99% concordance between professional and non-professional users

PRIMARY FIT

POINT OF CARE + SELF-TEST

GALILEO

Streamlined all-in-one platform



SIMPLIFIED BLOOD HANDLING

- Built-in, auto-retracting safety lancet
- Precise blood collection and delivery
- Patient-delivered buffer creates assay flexibility

PRIMARY FIT

POINT OF CARE + SELF-TEST

FLOREY

Modular clip-on usability upgrade



LOW-DISRUPTION CASSETTE UPGRADE

- Clips onto an existing blood-based cassette
- Adds precise button-activated buffer delivery
- Cassette remains readable by a validated reader

PRIMARY FIT

EXISTING COMMERCIAL TESTS

GLOBAL QUALITY & REGULATORY STRENGTH

Atomo's audited QMS supports registrations achieved directly and with partners

QUALITY FOUNDATION

External scrutiny

Regularly audited by multiple tier-one national regulators and the World Health Organization.

Measurable quality objectives

Business and product objectives are set at the levels required to meet product requirements.

IVDR-ready governance

QMS compliant with IVDR requirements for Class III and IV products.

FUTURE FOCUS

- MDSAP
- ACTIVE SYPHILIS — TGA / IVDR
- GEN 4 HIV — TGA / IVDR

CERTIFICATES & REGULATORY EVIDENCE



BSI / QMS



TGA



WHO PQ




CE



SAHPRA

GLOBAL REGULATORY FOOTPRINT



ATOMO — LISTED MANUFACTURER

HIV SELF TEST

TGA · Australia
WHO PQ · LMIC | CE Mark · UK & Europe

SYPHILIS / GEN 4 HIV – Future Filings

TGA · Australia
CE Mark · UK & Europe

PARTNER REGISTRATIONS

PREGNANCY TEST

CE Mark · UK & Europe | ANVISA · Brazil

LUMOS DIAGNOSTICS' FEBRIDX

FDA 510(k) + CLIA waiver · USA
CE Mark · UK & Europe | TGA · Australia
Health Canada · Canada

TWO PROVEN ENGINES FOR COMMERCIAL GROWTH

Commercial-stage diagnostics company pairing an established HIV franchise with a proven OEM platform

Proven and growing revenue bases validate the two scalable paths to diversified growth





ATOMO PROPRIETARY PRODUCT FRANCHISE

+21%

FY26 HIV SALES GROWTH | YOY

HIV GEN 3 DEMONSTRATES ATOMO'S ABILITY TO BUILD AND SCALE ITS OWN PRODUCTS

5m+ tests supplied across 30+ countries, with growth led by international supply and ANZ pharmacy channels.

OEM PARTNERSHIP BUSINESS

+209%

FY26 OEM REVENUE GROWTH | YOY


FEBRIDX® SHOWS THE POWER OF THE OEM PARTNERSHIP MODEL

Device supply increased 224% in 1Q27 YOY.

ATOMO PROPRIETARY PRODUCT PIPELINE

Commercial products fund a broader portfolio progressing through validation, development and feasibility





Proprietary portfolio spans established revenue products and new tests targeting decentralised professional and self-test markets.

OVERVIEW OF ATOMO'S GEN 3 HIV SELF-TEST

Integrated, highly accurate self-testing platform with established market adoption and expanding retail and public-health channels

TEST DIFFERENTIATION

15 MINUTES

Integrated, blood-based rapid diagnostic test designed for convenient, private and discreet self-testing.

SIMPLIFIES THE USER JOURNEY

All-in-one components and interlocked steps reduce procedural complexity and help mitigate common user errors.

PRODUCT + MARKET PROOF

99.6%

SENSITIVITY

identifies HIV-positive samples

99.6%

SPECIFICITY

identifies HIV-negative samples

5M+

TESTS SUPPLIED

to markets across more than 30 countries

Performance published by Atomo; reach and supply figures from company materials.



COMMERCIAL MOMENTUM

AUSTRALIAN MARKET LEADER

Across public and private channels, supported by national mail-out and vending-machine programs.

RETAIL EXPANSION

Chemist Warehouse in Australia and New Zealand, plus Tesco and Boots in the UK.

PUBLIC-HEALTH PROCUREMENT

Free-to-user access programs and government purchasing are emerging as long-term growth drivers.

ACTIVE SYPHILIS TRANSFERS TO MANUFACTURING

Program remains on schedule, with regulator engagement beginning and launch targeted within 18–24 months

TEST DIFFERENTIATION

15 MINUTES

Rapid lateral flow test for home-based and healthcare-practitioner-guided self-testing.

ADDRESSES A KEY TESTING GAP

Designed to detect infectious syphilis and distinguish active cases from previously treated cases.

EARLY CLINICAL PERFORMANCE

100%

SENSITIVITY

against active syphilis samples by clinical history

99%

SPECIFICITY

against never-infected patients

93%

SPECIFICITY

against previously treated cases with clinical history

Early clinical testing; results reported by clinical history.



PROGRAM ON SCHEDULE

TRANSFER COMPLETE

Test-strip manufacturing moved from Burnet Institute in Melbourne to Cape Town for clinical-trial production builds.

NEXT: CLINICAL TRIALS

Trials expected to commence early next year.

REGULATORY + LAUNCH

Engagement planned with TGA, FDA and BSI; commercial launch targeted within 18–24 months.

GEN 4 HIV PARTNERSHIP OPENS A NEW COMMERCIAL PATH

Global licence, development and supply agreement with Innovation Scientific

InnovationScientific

THE MOU AGREEMENT

Atomo to receive a global licence to commercialise a rapid Gen 4 HIV assay in its Galileo cassette.

Feasibility testing complete. The partnership now moves into final analytical/clinical studies and regulatory preparation.

Parties to negotiate final Supply Agreement and License over next four months.

WHO DOES WHAT

INNOVATION SCIENTIFIC

- Complete final assay development
- Run analytical and clinical studies with Atomo
- Integrate Galileo sub-assemblies with the strip and buffer for finished supply

ATOMO

- Manufacture and supply Galileo sub-assemblies
- Hold the global assay licence and act as legal manufacturer
- Lead IVDR and TGA registration, launch and commercialisation

COMMERCIAL PATH

18 MONTHS

Planned IVDR and TGA registration window

24 MONTHS

Target timing for commercial launch

A$1.16bn

HIV global rapid-test kit market


Source: Future Market Insights, 2026; Market Glass, Inc., 2026; MarketsandMarkets, 2025

STRATEGIC FIT Extends Atomo's Gen 3 HIV + Active Syphilis portfolio; own-pipeline revenue is targeted from late FY2028.

ALT LIVER TEST: LIVER-INJURY INSIGHT AT THE POINT OF CARE

A proven ALT assay on Atomo's Pascal platform creates multiple clinical, pharmaceutical and public-health pathways

TEST PROPOSITION



ALT

A key marker of liver damage used in diagnosis, treatment evaluation and disease monitoring.

DECENTRALISED TESTING


Fingerstick blood testing on the Pascal platform enables rapid liver-injury assessment at point of care and at home.

WORLDWIDE LICENCE

Burnet Institute assay; Atomo is the listed manufacturer and finished-test supplier

DEVELOPMENT + PERFORMANCE

Development is substantially complete; diagnostic performance has been established.



PERFORMANCE

Test shows good correlation (R2 = 0.9089) between fingerprick blood and venous blood

The validation set gave AUC 0.94 performance distinguishing normal from abnormal ALT at 40 IU/L



BROAD COMMERCIAL UTILITY

DILI MONITORING

Pharmaceutical and clinical-trial monitoring for drug-induced liver injury.

HEPATITIS MANAGEMENT

Supports treatment decisions and ongoing monitoring in hepatitis B and C.

LIVER-DISEASE SCREENING

Potential screening pathways in fatty-liver and alcohol-related liver disease.

OEM PARTNER PIPELINE

Atomo technology enables partner assays to move from technical validation into commercial supply at scale



PRODUCT / APPLICATION		FEASIBILITY	DEVELOPMENT	VALIDATION	COMMERCIAL
FEBRIDX®	Lumos · acute respiratory infection				COMMERCIAL
PREGNANCY	NG Biotech · early pregnancy detection				COMMERCIAL
FERRITIN	Chromacare · iron deficiency			VALIDATION	
BRAIN DISEASE	Upfront · pre-hospital triage			VALIDATION	

Atomo technology platforms support multiple partner assays—creating recurring device-supply opportunities as programs progress.

OEM pipeline focused on professional point-of-care markets and scalable partner supply.

FEBRIDX®: FINGERSTICK TO 10-MINUTE ANTIBIOTIC DECISION AID

Lumos' CLIA-waived test combines dual host-response biomarkers with Atomo's integrated Pascal platform

RAPID RESPIRATORY TRIAGE



A rapid, instrument-free point-of-care test that helps distinguish bacterial infection from non-bacterial causes—supporting more confident antibiotic decisions.

PRODUCT + COMMERCIAL OVERVIEW

FebriDx pairs Lumos' MxA + CRP host-response assay with Atomo's Pascal cassette for a simple, portable fingerstick workflow.

DIFFERENTIATE

Dual MxA + CRP biomarkers help separate bacterial infection from non-bacterial etiology.

DECIDE IN 10

A visual result after 10 minutes supports treatment decisions during the initial visit.

SCALE IN THE US

FDA CLIA waiver enables use at waived sites; Pascal delivered >99% trained/untrained concordance.

A$1.9m FY26 Atomo FebriDx orders—approximately 9× FY25—supporting recurring Pascal demand.

PASCAL OEM REVENUE PERFORMANCE

Strong YOY growth driven by Lumos Diagnostics' FebriDx

ATOMO OEM PERFORMANCE | FY26 YEAR-ON-YEAR

+209%

OEM SALES REVENUE

+224%

GROWTH IN DEVICES SUPPLIED



US FEBRIDX® ADOPTION | LUMOS-REPORTED

215

LIVE US SITES

September 2026

+26.5%

170 in July → 215 in September

405 sites under evaluation (350 in July)

March 2026 FDA CLIA waiver expanded eligible US testing settings.

OEM Momentum

Flu-season inventory build fuels triple-digit revenue and device-volume growth.

TWO BLOOD-BASED TESTS EXPAND PASCAL PLATFORM

NG Biotech pregnancy and Chromacare ferritin programs pair partner assays with an integrated fingerstick

NG BIOTECH | BLOOD PREGNANCY

NG Biotech's hCG assay and Atomo's all-in-one Pascal platform support both professional and self-testing settings.



5 MIN
QUALITATIVE RESULT

10 µL
FINGERSTICK SAMPLE

10 mIU/mL
DETECTION LIMIT

NG Biotech reports 100% sensitivity and specificity.

2 routes to market: professional testing + NG PRECISION+ consumer self-test.

CHROMACARE | FERRITIN

Chromacare's quantitative ferritin assay is being integrated into Pascal for professional and at-home iron-deficiency testing.



10 MIN
QUANTITATIVE RESULT

APP-GUIDED
READ, STORE + TRACK

PASCAL
INTEGRATED BLOOD HANDLING

Results can be tracked over time and shared with healthcare providers.

A$170k initial order supports product validation and regulatory registration.

Sources: NG Biotech Professional Tests and Self-Tests; Chromacare Labs ferritin test; Atomo Diagnostics Pascal and partner materials. Accessed 23 Oct 2026.

UPFRONT + ATOMO PARTNER ON NEXT-GENERATION TEST

Upfront's biomarker assay moves into Atomo's technology platform

UPFRONT
TIME IS LIFE

LVTwo

A rapid blood-based brain-disease test designed for use before hospital arrival—helping emergency teams triage suspected stroke or other brain-disease patients sooner.

PARTNERSHIP ANNOUNCEMENT

Atomo and Upfront announce partnership for Upfront's next-generation test in Atomo's device.

DETECT

Proprietary biomarker targets proteins associated with brain disease.

DEPLOY

Atomo hand-held devices combine blood collection, sample transfer and buffer delivery.

DECIDE EARLIER

Designed for pre-hospital use to support faster routing and treatment decisions.

9,000 Atomo sub-assemblies supplied for validation and verification activities to date

FY 2026 FINANCIALS

FY26 – PROFIT & LOSS

Revenue grew strongly and the underlying EBITDA loss narrowed by 39%

AUD	FY26 ($m)	FY25 ($m)	(%)
Revenue	**5.33**	**3.79**	**41%**
Cost of sales	(3.45)	(1.87)	
Gross Profit	**1.88**	**1.92**	**(2%)**
Gross Margin	**35%**	**51%**	
Other income	2.24	1.52	47%
Employee benefits expense	(2.88)	(3.26)	12%
Foreign exchanges gains/(losses)	(0.04)	(0.01)	(300%)
Research and development costs	(0.76)	(0.62)	(23%)
Professional fees expense	(0.49)	(0.95)	48%
Inventory obsolescence expense	(0.12)	(0.13)	8%
Other expenses	(1.89)	(1.85)	(2%)
Underlying EBITDA	**(2.06)**	**(3.38)**	**39%**

REVENUE

$5.33m

FY25 $3.79m

+41% YoY

GROSS MARGIN

35%

FY25 51%

-16 pts YoY

UNDERLYING EBITDA

($2.06m)

FY25 ($3.38m)

39% improvement

* Amounts in A$m; YoY compares FY26 with FY25

FY26 – BALANCE SHEET

FY26 closed with $3.71m in cash, $10.66m in assets and no bank debt

AUD	FY26 ($m)	FY25 ($m)
Cash and cash equivalents	3.71	3.22
Trade and other receivables	3.22	1.69
Inventories	1.97	1.65
Property, plant and equipment	0.34	0.89
Intangible assets	1.22	1.64
Other assets	0.36	0.18
Total assets	**10.82**	**9.27**
Trade and other payables	1.68	1.02
Other liabilities	1.43	1.28
Total liabilities	**3.11**	**2.30**
Net Assets	**7.71**	**6.97**

* Amounts in A$m; June 2026 audited actuals

CASH

$3.71m

available liquidity

TOTAL ASSETS

$10.66m

at June 2026


NO DEBT

$0

bank borrowings

FY26 CASHFLOW

Strong cash generation from sales, grants, and fundraising activities



TOTAL CASH RECEIPTS

$10.2m

$4.6m customer receipts

plus R&D rebate, CRC-P grant and capital

TOTAL CASH PAYMENTS

$9.7m

$4.1m stock purchases

$5.6m operating expenses

YEAR-END CASH

$3.7m


at 30 June 2026


no debt

FINANCIAL SUMMARY

FY2026 was a transitional year, showing strong and sustainable revenue growth with improving EBITDA


- ✓ Atomo is seeing strong momentum in its established revenue channels including HIV Testing and Pascal OEM
- ✓ Expansion of customer base across new partners for Pascal and an expanded Atomo test product pipeline





- ✓ Capital focus on new test portfolio development / commercialisation – Syphilis and Liver
- ✓ Non-dilutive funding grants (Syphilis) and selective licensing of proven assets (Liver) used to support lower-cost development and go to market
- ✓ EBITDA – continued trend towards breakeven as existing revenue channels grow and product offerings expand

- ✓ **Debt free balance sheet**
- ✓ Atomo validating a second-generation blister machine and high-cavity mould tooling to support expansion of capacity and improve economies of scale and margins



STRATEGIC IMPERATIVES FOR FY2027

Executing priorities focused on revenue growth, portfolio expansion, and scalable operations

FY26

Scale the core. Improve the margins. Expand the pipeline.

Atomo's priorities align commercial growth with manufacturing scale, disciplined cash management and the development of new finished tests.

Point-of-care and self-testing solutions designed around simple, integrated blood collection.

01 HIV MARKET EXPANSION

Grow established sales channels and secure new territory distribution partners.

02 PORTFOLIO EXPANSION

Advance finished tests beyond HIV, including Liver and blood pregnancy opportunities.

03 SYPHILIS & GEN 4 HIV DEVELOPMENT

Progress clinical and regulatory work for syphilis and Gen 4 HIV.

04 OPERATIONS & MARGINS

Scale Pascal output and improve margins through in-housing and economies of scale.

05 CASH DISCIPLINE

Maintain close control of operating costs and the use of cash.

06 PLATFORM ADOPTION

Add Pascal OEM customers and progress Florey with an initial customer.

BUILDING A STRONGER BASE FOR SCALABLE GROWTH

Commercial momentum is funding a broader product pipeline and a more diversified revenue base

$5.33m

FY26 REVENUE | +41% YoY

HIV franchise +21% YoY
OEM revenue +209% YoY

HIV FRANCHISE LEADS COMMERCIAL TRACTION

HIV sales increased 21% year on year, led by international supply and ANZ pharmacy and public health channels.

FEBRIDX® SHOWS THE POWER OF THE OEM MODEL

OEM revenue reached $2.2m, up 209% year on year, while device supply increased 224%.

DIVERSIFICATION BUILDS OVER TIME

Commercial HIV, pregnancy, and FebriDx® provide the commercial base as the proprietary pipeline and OEM programs in syphilis, Gen 4 HIV, stroke, ferritin, and earlier-stage assays advance.



A stronger HIV franchise and scalable OEM model support a broader, more diversified growth platform over time.